Apogossypolone inhibits cell growth by inducing cell cycle arrest in U937 cells

Oncology Reports

Volumn 22, Issue 1, 2009, Pages 193-198

  Sun, Jian ^a,b   Li, Zhi Ming ^a,b   Hu, Zhe Yu ^a,b   Zeng, Zhao Lei ^a,b   Yang, Da Jun ^c   Jiang, Wen Qi ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c Ascenta Therapeutics   (United States)

Author keywords

ApoG2; Cell cycle arrest; Cyclin; Cyclin dependent kinases; U937

Indexed keywords

ANTINEOPLASTIC AGENT; APOGOSSYPOLONE; CASPASE 3; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN E; CYCLINE; CYTOCHROME C; GOSSYPOL DERIVATIVE; MYC PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL STRAIN U937; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME RELEASE; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN D1; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOCHROMES C; DOSE-RESPONSE RELATIONSHIP, DRUG; GOSSYPOL; HUMANS; LYMPHOMA; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS C-MYC; TIME FACTORS; U937 CELLS;

EID: 68249160072     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000424     Document Type: Article

References (29)

1. Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature 411: 342-348, 2001.
2. Debatin K: Activation of apoptosis pathways by anticancer treatment. Toxicol Lett 112-113: 41-48, 2000.
3. Stewart ZA, Westfall MD and Pietenpol JA: Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol Sci 24: 139-145, 2003.
4. Sandal T: Molecular aspects of the mammalian cell cycle and cancer. Oncologist 7: 73-81, 2002.
5. Schmitt CA: Senescence, apoptosis and therapy - cutting the lifelines of cancer. Nat Rev Cancer 3: 286-295, 2003.
6. Nigg EA: Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. Bioessays 17: 471-480, 1995.
7. Owa T, Yoshino H, Yoshimatsu K, et al: Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr Med Chem 8 1487-1503, 2001.
8. Deigner HP and Kinscherf R: Modulating apoptosis: current applications and prospects for future drug development. Curr Med Chem 6: 399-414, 1999.
9. Wang X, Wang J, Wong SC, et al: Cytotoxic effect of gossypol on colon carcinoma cells. Life Sci 67: 2663-2671, 2000.
10. Oliver CL, Bauer JA, Wolter KG, et al: In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res 10: 7757-7763, 2004.
11. Mohammad RM, Wang S, Aboukameel A, et al: Preclinical studies of a non-peptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. Mol Cancer Ther 4: 13-21, 2005.
12. Xu L, Yang D, Wang S, et al: (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. Mol Cancer Ther 4: 197-205, 2005.
13. Sun Y, Wu J, Aboukameel A, et al: Apogossypolone, a non-peptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo. Cancer Biol Ther 7: 1418-146, 2008.
14. Hu ZY, Zhu XF, Zhong ZD, et al: ApoG2, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces apoptosis and suppresses tumor growth in nasopharyngeal carcinoma xenografts. Int J Cancer 123: 2418-2429, 2008.
15. Arnold AA, Aboukameel A, Chen J, et al: Preclinical studies of Apogossypolone: a new non-peptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model. Mol Cancer 7: 20, 2008.
16. Sun J, Li ZM, Hu ZY, et al: ApoG2 inhibits antiapoptotic Bcl-2 family proteins and induces mitochondria-dependent apoptosis in human lymphoma U937 cells. Anticancer Drugs 19: 967-974, 2008.
17. Zou H, Henzel WJ, Liu X, et al: Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90: 405-413, 1997.
18. Li P, Nijhawan D, Budihardjo I, et al: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91: 479-489, 1997.
19. Herr I and Debatin KM: Cellular stress response and apoptosis in cancer therapy. Blood 98: 2603-2614, 2001.
20. Kaufmann SH and Earnshaw WC: Induction of apoptosis by cancer chemotherapy. Exp Cell Res 256: 42-49, 2000.
21. Sherr CJ and Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9: 1149-1163, 1995.
22. Agami R and Bernards R: Convergence of mitogenic and DNA damage signaling in the G1 phase of the cell cycle. Cancer Lett 177: 111-118, 2002.
23. Baldin V, Lukas J, Marcote MJ, et al: Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 7: 812-821, 1993.
24. Tsai LH, Lees E, Faha B, et al: The cdk2 kinase is required for the G1-to-S transition in mammalian cells. Oncogene 8: 1593-1602, 1993.
25. Matsumura I, Tanaka H and Kanakura Y: E2F1 and c-Myc in cell growth and death. Cell Cycle 2: 333-338, 2003.
26. Fulda S and Debatin KM: Death receptor signaling in cancer therapy. Curr Med Chem Anticancer Agents 3: 253-262, 2003.
27. Mayer B and Oberbauer R: Mitochondrial regulation of apoptosis. News Physiol Sci 18: 89-94, 2003.
28. Alnemri ES, Livingston DJ, Nicholson DW, et al: Human ICE/CED-3 protease nomenclature. Cell 87: 171, 1996.
29. Hajnoczky G, Davies E and Madesh M: Calcium signaling and apoptosis. Biochem Biophys Res Commun 304: 445-454, 2003.